Fibrobiologics, Inc. (FBLG) 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fibrobiologics, Inc. on April 3, 2026, covering events occurring on March 30, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "FBLG".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding the Company's capital structure.
Material Changes
The primary material change reported is the implementation of a one-for-twenty (1:20) reverse stock split of the Company's issued and outstanding common stock. Key details include:
- Effective Date: March 30, 2026, at 12:01 a.m. Eastern Time.
- Conversion Ratio: Every 20 shares of pre-split common stock were converted into 1 share of post-split common stock.
- Fractional Shares: No fractional shares were issued; any fractional entitlements were rounded up to the nearest whole share.
- Ownership Impact: The split affects all stockholders uniformly and does not alter percentage ownership interests, except for rounding adjustments.
- Equity Adjustments: The number of shares available under the equity incentive plan, as well as the exercise prices and share counts for outstanding stock options and warrants, were proportionately adjusted.
- Identifiers: The CUSIP number changed to 31573L204. The trading symbol remains "FBLG". The par value ($0.00001) and authorized share count remain unchanged.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the execution of the reverse stock split.
Investor Verification Checklist
- Verify the updated CUSIP number (31573L204) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts reflects the 1:20 ratio and rounding rules.
- Review the adjusted exercise prices and share quantities for any outstanding stock options or warrants.
- Check the Company's equity incentive plan for the adjusted number of shares available for future grants.